RNA Vaccines

mRNA manufacturing

BiologIC is applying its proprietary technology to develop a next generation mRNA manufacturing capability.  The development forms part of the UK government's UK Vaccine Network looking at ways to tackle "Disease X" - a hypothetical future pathogen.

One of the greatest challenges faced by humanity is to eliminate the existential threat of infectious diseases including zoonotic pandemics such as a future Disease X.  BiologIC is helping build a world-leading RNA vaccine capability that allows humanity to mitigate infectious diseases in an environmentally sustainable and economically accessible manner. 

Vaccines are one of the great success stories of modern medicine, having eradicated or controlled many severe infections of major global importance and improved the lives of millions.  However, infectious diseases kill 17 million people per annum, prior to COVID19, and at least 30 new such diseases have emerged in the last 20 years.

Synthetic RNA medicines are becoming critical treatments for infectious diseases (such as COVID19, influenza, rabies and Marburg) and as personalised therapies.  Currently, RNA vaccines are manufactured using equipment and approaches transferred from biologics manufacture.

BiologIC is the inventor of the biocomputer.  BiologIC uses advanced additive manufacturing to fabricate powerful new bioprocessors for manufacture of bioproducts including vaccines.  The bioprocessors integrate common workflows, are highly scalable and address multiple application areas. The bioprocessors significantly increase bioprocessing power and distribute bioprocessing to the point-of-need.

BiologIC is developing bioprocessors operated on its biocomputer system to enable distributed biomanufacturing of RNA vaccines.  The system will substantially reduce vaccine costs and distribute flexible manufacturing to any point of need in rapidly evolving supply chains.  The system is inspired by computer architectures for bioprocessing power and rapid scale-out production.

Our ambition is that the system helps reduce deaths and illness from infectious diseases through affordable and equitable access to vaccines by people of diverse socio-economic groups on-demand around the world.